(Q44282851)

English

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

scientific article published on 30 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Ana Ruiz-Garcia

object named as

Ana Ruiz-Garcia

6

0 references

author name string

D Ross Camidge

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Normand Blais

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Derek J Jonker

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Denis Soulières

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Robert C Doebele

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Aron Thall

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Ke Zhang

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Scott A Laurie

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Richard C Chao

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Laura Q Chow

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

30 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

307-319

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

https://scigraph.springernature.com/pub.10.1007/s00280-012-2008-6

0 references

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Sunitinib efficacy against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-2008-6

21 January 2018

Identifiers

10.1007/S00280-012-2008-6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44282851&oldid=2143426192"